• Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers.
    • Corso G, Robson ME, Sacchini V.
    • Ann Surg Oncol. 2022 May 23. doi: 10.1245/s10434-022-11913-6. Epub ahead of print.
    • Review, Commentary
    • Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies.
    • Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, Luchini C, Jereczek-Fossa BA, Sapino A, Cinieri S; Italian Scientific Societies.
    • ESMO Open. 2022 May 18;7(3):100459. doi: 10.1016/j.esmoop.2022.100459. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
    • Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, Garber JE, Meric-Bernstam F.
    • JAMA Netw Open. [2022 May 20];5(5):e2213070. doi: 10.1001/jamanetworkopen.2022.13070.

    Ccommentary:

    Paired Tumor-Germline Testing as a Driver in Better Cancer Care.

    • Breast cancer risk for transgender men with inherited mutations.
    • [No author given]
    • FORCE. XRAY. 2022 May 19.

    Commentary:

    BRCA Mutations and the Implications in Transgender Individuals Undergoing Top Surgery: An Operative Dilemma.

  • LitAlert ~~ GeneLit.com

    • Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling.
    • Kondo T, Yamamoto Y, Fukuyama K, Kanai M, Yamada A, Matsubara J, Quy PN, Yoshioka M, Yamada T, Minamiguchi S, Matsumoto S, Kosugi S, Muto M.
    • Int J Clin Oncol. 2022 May 14. doi: 10.1007/s10147-022-02176-y. Epub ahead of print.
    • A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer.
    • Hughes KS, Yin K.
    • Ann Surg Oncol. 2022 May 12. doi: 10.1245/s10434-022-11860-2. Epub ahead of print.
    • Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients.
    • Espinel W, Champine M, Hampel H, Jeter J, Sweet K, Pilarski R, Pearlman R, Shane K, Brock P, Westman JA, Kipnis L, Sotelo J, Chittenden A, Culver S, Stopfer JE, Schneider KA, Sacca R, Koeller DR, Gaonkar S, Vaccari E, Kane S, Michalski ST, Yang S, Nielsen SM, Bristow SL, Lincoln SE, Nussbaum RL, Esplin ED.
    • Cancers (Basel). 2022 May 13;14(10):2426. doi: 10.3390/cancers14102426.
    • The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.
    • de Oliveira JM, Zurro NB, Coelho AVC, Caraciolo MP, de Alexandre RB, Cervato MC, Minillo RM, de Vasconcelos Carvalho Neto G, Grivicich I, Oliveira JB.
    • Eur J Hum Genet. 2022 May 9. doi: 10.1038/s41431-022-01098-7. Epub ahead of print.
    • Prenatal genetic counseling practices regarding recommendations for cancer genetic counseling: A retrospective chart review from two academic institutions.
    • Saba LF, Sullivan CM, Solomon T, Huguenard S, Nassef SA.
    • J Genet Couns. 2022 Apr 18. doi: 10.1002/jgc4.1577. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    • Smith M, Pothuri B.
    • Curr Treat Options Oncol. 2022 Apr 12. doi: 10.1007/s11864-022-00938-4. Epub ahead of print.
    • Review
    • Preimplantation genetic testing in patients with genetic susceptibility to cancer.
    • Villy MC, Frydman N, Moutou C, Thierry G, Raad J, Colas C, Steffann J, Metras J, Chabbert-Buffet N, Parc Y, Richard S, Benusiglio PR.
    • Fam Cancer. 2022 Apr 12. doi: 10.1007/s10689-022-00293-1. Epub ahead of print.